Ontology type: schema:ScholarlyArticle Open Access: True
2019-12
AUTHORSElizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
ABSTRACTBACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored. METHODS: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed. RESULTS: A total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy. CONCLUSION: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy. More... »
PAGES49
http://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3
DOIhttp://dx.doi.org/10.1186/s40425-019-0522-3
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1112212877
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30777131
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Immunology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Dana\u2013Farber Cancer Institute",
"id": "https://www.grid.ac/institutes/grid.65499.37",
"name": [
"Dana Farber Cancer Institute, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "Buchbinder",
"givenName": "Elizabeth I.",
"type": "Person"
},
{
"affiliation": {
"name": [
"Cancer Research Foundation of NY, Chappaqua,, NY, USA"
],
"type": "Organization"
},
"familyName": "Dutcher",
"givenName": "Janice P.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of California, San Diego",
"id": "https://www.grid.ac/institutes/grid.266100.3",
"name": [
"Moores UCSD Cancer Center, La Jolla, San Diego, CA, USA"
],
"type": "Organization"
},
"familyName": "Daniels",
"givenName": "Gregory A.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Providence Health & Services",
"id": "https://www.grid.ac/institutes/grid.415286.c",
"name": [
"Providence Health & Services, Portland, OR, USA"
],
"type": "Organization"
},
"familyName": "Curti",
"givenName": "Brendan D.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "The University of Texas MD Anderson Cancer Center",
"id": "https://www.grid.ac/institutes/grid.240145.6",
"name": [
"The University of Texas MD Anderson Cancer Center, 77030, Houston, TX, USA"
],
"type": "Organization"
},
"familyName": "Patel",
"givenName": "Sapna P.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Minnesota",
"id": "https://www.grid.ac/institutes/grid.17635.36",
"name": [
"University of Minnesota, Minneapolis, MN, USA"
],
"type": "Organization"
},
"familyName": "Holtan",
"givenName": "Shernan G.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hematology\\Oncology Clinic",
"id": "https://www.grid.ac/institutes/grid.490187.3",
"name": [
"Hematology/Oncology Clinic, Baton Rouge, LA, USA"
],
"type": "Organization"
},
"familyName": "Miletello",
"givenName": "Gerald P.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Moffitt Cancer Center",
"id": "https://www.grid.ac/institutes/grid.468198.a",
"name": [
"Moffitt Cancer Center, Tampa, FL, USA"
],
"type": "Organization"
},
"familyName": "Fishman",
"givenName": "Mayer N.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Colorado Anschutz Medical Campus",
"id": "https://www.grid.ac/institutes/grid.430503.1",
"name": [
"University of Colorado, Aurora, CO, USA"
],
"type": "Organization"
},
"familyName": "Gonzalez",
"givenName": "Rene",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Loyola University Chicago",
"id": "https://www.grid.ac/institutes/grid.164971.c",
"name": [
"Loyola University Stritch School of Medicine, Maywood, IL, USA"
],
"type": "Organization"
},
"familyName": "Clark",
"givenName": "Joseph I.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Saint Louis University",
"id": "https://www.grid.ac/institutes/grid.262962.b",
"name": [
"Saint Louis University, 63110, Saint Louis, MO, USA"
],
"type": "Organization"
},
"familyName": "Richart",
"givenName": "John M.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Michigan\u2013Ann Arbor",
"id": "https://www.grid.ac/institutes/grid.214458.e",
"name": [
"University of Michigan, Ann Arbor, MI, USA"
],
"type": "Organization"
},
"familyName": "Lao",
"givenName": "Christopher D.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Fred Hutchinson Cancer Research Center",
"id": "https://www.grid.ac/institutes/grid.270240.3",
"name": [
"University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
],
"type": "Organization"
},
"familyName": "Tykodi",
"givenName": "Scott S.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rutgers University",
"id": "https://www.grid.ac/institutes/grid.430387.b",
"name": [
"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"
],
"type": "Organization"
},
"familyName": "Silk",
"givenName": "Ann W.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Beth Israel Deaconess Medical Center",
"id": "https://www.grid.ac/institutes/grid.239395.7",
"name": [
"Beth Israel Deaconess Medical Center, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "McDermott",
"givenName": "David F.",
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s1470-2045(16)30126-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002679693"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1414428",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007696832"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-11-1823",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010268280"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(14)60958-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012632588"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/(sici)1097-0142(19980815)83:4<797::aid-cncr25>3.0.co;2-m",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015678740"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0092-8674(93)90152-g",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016163477"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1510665",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019970557"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1504030",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024843336"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1172/jci67008",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046164943"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2013.53.0105",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047895673"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1003466",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052212829"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.1995.13.3.688",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1082550218"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s40425-018-0387-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1105882929",
"https://doi.org/10.1186/s40425-018-0387-x"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-12",
"datePublishedReg": "2019-12-01",
"description": "BACKGROUND: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy following anti-PD-1 or anti-PD-L1 therapy have not yet been explored.\nMETHODS: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed.\nRESULTS: A total of 57 patients (40\u2009mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4 complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2 observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2 requiring steroid therapy.\nCONCLUSION: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.",
"genre": "research_article",
"id": "sg:pub.10.1186/s40425-019-0522-3",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1049249",
"issn": [
"2051-1426"
],
"name": "Journal for ImmunoTherapy of Cancer",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "7"
}
],
"name": "Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition",
"pagination": "49",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"146eee18ba798c34ddab163ca5fb25a2f73b2b963ebe466713cabcacbddbd2ae"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30777131"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101620585"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s40425-019-0522-3"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1112212877"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s40425-019-0522-3",
"https://app.dimensions.ai/details/publication/pub.1112212877"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T10:35",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113664_00000005.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1186%2Fs40425-019-0522-3"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-019-0522-3'
This table displays all metadata directly associated to this object as RDF triples.
232 TRIPLES
21 PREDICATES
42 URIs
21 LITERALS
9 BLANK NODES